Fierce Pharma

OCTOBER 30, 2024

Following reports of an ex-AstraZeneca executive being detained in China, the company acknowledged that its current president in the country, Leon Wang, "is cooperating with an ongoing investigatio | Following a report of an ex-AstraZeneca executive being detained in China, the company acknowledged that its current president in the country, Leon Wang, "is cooperating with an ongoing investigation.

271

271

pharmaphorum

OCTOBER 30, 2024

Novartis says FDA approval for frontline use of its leukaemia drug Scemblix will boost the number of eligible patients four-fold, as it hunts blockbuster sales

FDA 115

FDA Sales Patients 115

Fierce Pharma

OCTOBER 30, 2024

Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.

Prospecting 238

Prospecting Medicine FDA 238

pharmaphorum

OCTOBER 30, 2024

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for drugs in its class.Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the period used to achieve therapeutic levels in the body – is enough to lower the incidence of a potentially serious side effect known as ARIA-E, accordi

Side effects 111

Side effects 111

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Fierce Pharma

OCTOBER 30, 2024

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculat | Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of analyst expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation that skyrocketing demand for the blood sugar modulating treatments has maxed out.

Sales 218

Sales Leads 218

MedCity News

OCTOBER 30, 2024

The status quo is simply untenable for many companies as health insurance costs spiral. From family-owned businesses to large enterprises, employers are taking advantage of an alternative designed by politicians on both sides of the aisle. The post How a Bipartisan Program Can Help You Avoid Costly Health Insurance Renewals appeared first on MedCity News.

Insurance 93

Insurance Healthcare Healthcare 93

pharmaphorum

OCTOBER 30, 2024

The UK's first female Chancellor Rachel Reeves pumps billions into NHS in the first Labour budget in 14 years

108

108

Fierce Pharma

OCTOBER 30, 2024

Baxter International plans to exit China’s intravenous fluids market, multiple local media outlets report, citing a letter to distributors. | Baxter plans to exit China's IV fluids market as it faces tough local competition and as it redirects global IV supplies to the U.S. to cope with a post-hurricane shortage.

Competition 169

Competition Marketing Media 169

MedCity News

OCTOBER 30, 2024

Truth is, there are hugely positive tailwinds at our back. But the way we’ve been thinking about the problem is holding us back from solving it. Here’s why. The post Dear Mr. Buffett: Healthcare Isn’t Hopeless appeared first on MedCity News.

Healthcare 82

Healthcare Healthcare Physicians 82

Fierce Pharma

OCTOBER 30, 2024

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, Skyrizi is now on top for the Illinois pharma giant. This year, AbbVie's Humira successors are expected to bring in revenues of $17 billion.

Sales 157

Sales Pharma 157

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

MedCity News

OCTOBER 30, 2024

After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there’s still a way forward for psychedelic medicines, experts said at HLTH. The post What’s Next for Psychedelic Medicines? appeared first on MedCity News.

Medicine 68

Medicine FDA 68

Fierce Pharma

OCTOBER 30, 2024

Biopharma production efforts are set to receive a big boost in the U.K. thanks to a new budget rolled out by the Labour Party following this summer’s general election. | As part of the new budget presented Wednesday by the U.K.’s Chancellor of the Exchequer, Rachel Reeves, the country is debuting a new capital grants vehicle known as the Life Sciences Innovative Manufacturing Fund.

Manufacturing 153

Manufacturing Biopharma Medical 153

MedCity News

OCTOBER 30, 2024

The FDA had asked Biogen and Sage Therapeutics to provide more clinical data supporting Zurzuvae in major depressive disorder. Citing the time and expense of additional clinical trials, the partners decided against further development in this indication The post Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder appeared first on MedCity News.

FDA 62

FDA Biopharma Pharma 62

Fierce Pharma

OCTOBER 30, 2024

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug maker’s clutch of approved therapies under its fold. | In the third quarter, the company's overall sales grew 23% year over year and 8% excluding contributions from its Horizon Therapeutics buyout to $8.5 billion.

130

130

Advertisement

Pharmaceutical Technology

OCTOBER 30, 2024

GlaxoSmithKline (GSK) has entered an agreement to acquire Chimagen Biosciences’ CMG1A46 for $300m upfront.

83

83

Fierce Pharma

OCTOBER 30, 2024

Several recent developments have caused many people in our industry to think differently about affordability and access. | GoodRx’s integrated platform gives pharma companies a seamless way to deliver value to consumers and HCPs at scale while navigating today’s complex healthcare system.

Pharma 130

Pharma Healthcare Healthcare 130

pharmaphorum

OCTOBER 30, 2024

The head of AstraZeneca's Chinese operations, Leon Wang, has been placed under investigation by the authorities in Beijing

64

64

Fierce Pharma

OCTOBER 30, 2024

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 million, falling short of consensus estimates. But behind the scenes, there was a 40% uptick in the number of new prescribers writing prescriptions for Leqembi in the third quarter versus Q2, Alicia Alaimo, Biogen’s president and head of North America, said Wednesday.

Prescription 120

Prescription Sales 120

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

ALULA

OCTOBER 30, 2024

In an era of rapid change, the most dangerous phrase in business is, “We've always done it this way.” Yet, many leaders struggle to adapt, stuck in outdated approaches. But what if you could break free from the status quo and lead your team into a brighter, more innovative future?

Leads 52

Leads 52

PharmExec

OCTOBER 30, 2024

The trials will investigate datopotamab deruxtecan in combination with treatments including rilvegostomig, osimertinib, and chemotherapy in patients with nonsquamous non-small cell lung cancer.

Patients 52

Patients 52

European Pharmaceutical Review

OCTOBER 30, 2024

A paper has a described the first reported use of nanoemulsions as a novel delivery vehicle for the oral drug bedaquline (BDQ) “with high loading efficiency as a liquid dosage form”, according to the authors. The researchers explained that in recent decades, the industry has placed significant focus on lipid-based nanocarrier formulations for oral drug delivery.

Manufacturing 52

Manufacturing Pharmaceutical 52

PharmExec

OCTOBER 30, 2024

Accelerated approval is based on results of the ASC4FIRST Phase III trial, which demonstrated Scemblix's superior efficacy in achieving major molecular response compared to standard of care tyrosine kinase inhibitors in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

FDA 52

FDA Patients 52

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

Pharmaceutical Commerce

OCTOBER 30, 2024

In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.

Healthcare Provider 52

Healthcare Provider Healthcare Healthcare Medical 52

PharmExec

OCTOBER 30, 2024

By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.

Pharma 52

Pharma Competition Leads 52

PharmaTech

OCTOBER 30, 2024

The company will be expanding its quality control testing capabilities at its San Diego, Calif. biologics development and manufacturing site.

Manufacturing 59

Manufacturing 59

PharmExec

OCTOBER 30, 2024

Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding explore solutions for the current supply chain challenges and improve patient access to medications.

Patients 52

Patients Medical 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

OCTOBER 30, 2024

Sales of GSK's RSV vaccine Arexvy plummet in Q3 after change to US usage advice, but Pfizer's rival Abrysvo holds up much better

Sales 59

Sales 59

PharmaTech

OCTOBER 30, 2024

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry experts who recently exhibited at CPHI Milan.

52

52

PharmaVoice

OCTOBER 30, 2024

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.

Competition 59

Competition Marketing 59

PharmExec

OCTOBER 30, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Healthcare 52

Healthcare Healthcare Pharma 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales